Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Multicenter, Phase 3 Study for Efficacy and Safety Assessment of DHP107 (Oral Paclitaxel) vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy With Fluoropyrimidine +/- Platinum

NCT01839773 is registered in ClinicalTrials.gov with Daehwa Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT01839773
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01839773 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Multicenter, Phase 3 Study for Efficacy and Safety Assessment of DHP107 (Oral Paclitaxel) vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy With Fluoropyrimidine +/- Platinum
Lead sponsor
Daehwa Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2013
Completion date
August 31, 2015
Enrollment
238 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

stage iv gastric cancer